Navigation Links
Celladon Corporation Receives Patent from United States Patent and Trademark Office
Date:7/19/2012

SAN DIEGO, July 19, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,221,738 with claims that cover the administration of MYDICAR, Celladon's first in class drug under clinical evaluation for advanced heart failure. The patent, titled "Methods of enhanced uptake of viral vectors in the myocardium" carries a patent term to at least March, 2030. A similar application has been filed with the EU Patent Office (EPO).

"This is yet another important addition to our evolving patent portfolio for MYDICAR. The allowance further strengthens MYDICAR's market exclusivity protection in the United States" said Krisztina Zsebo Ph.D., President and CEO of Celladon Corp. "This is the second important patent granted to MYDICAR this year and we will continue the pursuit of additional patent grants relevant to our products on a global basis."

About MYDICAR

MYDICAR is a genetically targeted enzyme replacement therapy intended to restore levels of SERCA2a, a regulator of calcium cycling in the heart and cardiac contractility. SERCA2a levels decline in all forms of late-stage heart failure resulting in deficient heart function. With MYDICAR, the SERCA2a gene is delivered using recombinant adeno-associated virus (AAV) as the vector. AAV is a naturally occurring virus not associated with any disease in humans. MYDICAR is delivered in a single dose directly to the heart during a routine outpatient cardiac catheterization procedure, similar to an angiogram. MYDICAR is synergistic and additive across current heart failure treatments such as ACE inhibitors, beta-blockers, sprinolactone/diuretics, and biventricular pacing devices. No treatment substitution decision is required by the treating physician.

About Heart Failure

Chronic heart failure is a leading cause of hospitalization and is expected to result in direct and indirect costs of $39.2 billion to the U.S. healthcare system in 2010. Nearly 6 million people in the U.S. have heart failure, and at least 670,000 new cases will be diagnosed this year. Heart failure leads to about 280,000 deaths annually. The most common symptoms of heart failure are shortness of breath, feeling tired and swelling in the ankles, feet, legs and sometimes the abdomen. There is no cure.


'/>"/>
SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Celladon Corporation Receives Notice of Allowance from European Patent Office
2. Gentris Corporation Launches New Pharmacogenomics Services
3. BioElectronics Corporation Announces Initiative for UK and German Markets
4. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
5. Luminex Corporation Announces Agreement to Acquire GenturaDx
6. Statement from Mary Vogt, President of Home Access Health Corporation, manufacturer of the Home Access HIV-1 test system, the only over-the-counter HIV test previously approved by the FDA for at-home use.
7. Gentris Corporation Partners with the Shanghai Institutes of Preventative Medicine
8. BioElectronics Corporation Announces Indian Distributors Ecommerce Website
9. FMC Corporation Acquires Phytone, Ltd., a Leading European Natural Colors Business
10. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
11. Centene Corporation Selected for Ohio Medicaid Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
Breaking Medicine News(10 mins):